Methods of Treatment Using Anti-IL-17A/F Antibodies

Abstract

The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.

1 .- 25 . (canceled) 
     
     
         26 . A method of reducing psoriasis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F. 
     
     
         27 . The method of  claim 26 , wherein the psoriasis is plaque psoriasis. 
     
     
         28 . The method of  claim 26 , wherein the reduction of plaque psoriasis is measured by PASI criteria. 
     
     
         29 . The method of  claim 26 , comprising administering an amount of antibody that achieves at least a 75% or 90% change in lesion severity score (LSS) compared to pre-treatment at four, six, or eight weeks following administration of the antibody. 
     
     
         30 . The method of  claim 26 , comprising administering an amount of antibody that achieves at least a 75% or 90% change in Psoriasis Area and Severity Index (PASI) compared to pre-treatment at four, six, or eight weeks following administration of the antibody. 
     
     
         31 .- 83 . (canceled) 
     
     
         84 . The method of treating psoriasis of any one of  claims 26 - 30  and  33 - 35 , wherein the method comprises administering (a) 64 mg of antibody every four weeks, (b) 160 mg of antibody every four weeks or every 8 weeks, (c) 320 mg of antibody every four weeks or every eight weeks, (d) 320 mg loading dose of antibody followed by a maintenance dose of 160 mg of antibody every four weeks, or (e) 480 mg of antibody every four weeks. 
     
     
         85 .- 88 . (canceled) 
     
     
         89 . A method of treating psoriatic arthritis, psoriasis, rheumatoid arthritis or ankylosing spondylitis in a human, comprising the step of administering to the human a loading dose of a neutralizing antibody which binds human IL-17A and human IL-17F followed by at least one maintenance dose of the antibody. 
     
     
         90 .- 124 . (canceled)